ATYR Atyr Pharma Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ATYR

Price (delayed)

$0.5244

Market cap

$51.42M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.73

Enterprise value

$51.31M

?
Relative Growth: Rel. Growth: 10
Relative Strength: Rel. Strength: 1
Relative Valuation: Rel. Valuation: 1
Relative Profitability: Rel. Profitability: 28

atyr pharma (nasdaq: life) is engaged in the discovery and clinical development of innovative medicines for patients suffering from severe rare diseases using its knowledge of physiocrine biology, a newly ...

Highlights
The debt has contracted by 10% YoY and by 2.8% from the previous quarter
ATYR's EPS is up by 9% since the previous quarter and by 9% year-on-year
Atyr Pharma's quick ratio has decreased by 21% YoY but it has increased by 9% from the previous quarter
The net income has contracted by 10% YoY but it has grown by 6% from the previous quarter
The company's equity fell by 23% YoY and by 14% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: https://www.atyrpharma.com/
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of ATYR

ATYR stock price

How has the Atyr Pharma stock price performed over time
Intraday
4.86%
1 week
7.59%
1 month
-37.79%
1 year
-89.8%
YTD
-33.04%
QTD
-32.77%

Financial performance

How have Atyr Pharma's revenue and profit performed over time
Revenue
$190,000
Gross profit
$190,000
Operating income
-$73.29M
Net income
-$70.03M
Gross margin
100%
Net margin
-36,857.4%
The net income has contracted by 10% YoY but it has grown by 6% from the previous quarter
Atyr Pharma's operating income has decreased by 9% YoY but it has increased by 6% from the previous quarter
ATYR's operating margin is up by 6% since the previous quarter
The net margin has grown by 6% from the previous quarter

Price vs fundamentals

How does ATYR's price correlate with its fundamentals

Growth

What is Atyr Pharma's growth rate over time

Valuation

What is Atyr Pharma stock price valuation
P/E
N/A
P/B
0.89
P/S
270.6
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
270.03
ATYR's EPS is up by 9% since the previous quarter and by 9% year-on-year
ATYR's P/B is 63% below its last 4 quarters average of 2.3 and 53% below its 5-year quarterly average of 1.8
The company's equity fell by 23% YoY and by 14% QoQ

Efficiency

How efficient is Atyr Pharma business performance
The company's return on invested capital fell by 19% YoY
The return on equity has declined by 15% year-on-year
The ROA has contracted by 14% YoY
ATYR's ROS is up by 6% since the previous quarter

Dividends

What is ATYR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ATYR.

Financial health

How did Atyr Pharma financials performed over time
The current ratio has contracted by 26% YoY but it has grown by 9% from the previous quarter
Atyr Pharma's quick ratio has decreased by 21% YoY but it has increased by 9% from the previous quarter
The debt is 80% less than the equity
The company's equity fell by 23% YoY and by 14% QoQ
ATYR's debt to equity is up by 18% YoY and by 11% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.